NanoString Technologies
NanoString Technologies Inc (Form: 8-K, Received: 05/10/2017 12:12:29)

Washington, DC 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 9, 2017  
NanoString Technologies, Inc.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
of incorporation)
File Number)
(IRS Employer
Identification No.)

530 Fairview Avenue North
Seattle, Washington 98109
(Address of principal executive offices, including zip code)

(206) 378-6266
(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act).    ¨

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 9, 2017, the board of directors of NanoString Technologies, Inc. (the “Company”), upon recommendation from the nominating and corporate governance committee of the Company’s board of directors, voted to appoint Elisha W. Finney, as a director of the Company, effective immediately. Ms. Finney was appointed as a Class II director with a term expiring at the Company’s 2018 annual meeting of stockholders. Ms. Finney was also appointed to the audit committee of the Company’s board of directors and designated as an audit committee financial expert.

There are no transactions and no proposed transactions between Ms. Finney (or any member of her immediate family) and the Company (or any of its subsidiaries), and there is no arrangement or understanding between Ms. Finney and any other person or entity pursuant to which Ms. Finney was appointed as a director of the Company.

Ms. Finney will participate in the Company’s standard compensation plan for non-employee directors, including an initial stock option grant, which was granted to Ms. Finney on May 9, 2017. The standard compensation plan for non-employee directors is described in the section entitled "Director Compensation Program" of the Company's definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on April 28, 2017.

A press release announcing Ms. Finney’s appointment to the board of directors is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
NanoString Technologies, Inc. Press release dated May 10, 2017.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NanoString Technologies, Inc.
May 10, 2017
/s/ R. Bradley Gray
R. Bradley Gray
President and Chief Executive Officer


Exhibit No.
NanoString Technologies, Inc. Press release dated May 10, 2017.

Exhibit 99.1


NanoString Technologies Appoints Elisha W. Finney to Board of Directors

SEATTLE, May 10, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), ), a provider of life science tools for translational research and molecular diagnostic products, today announced the appointment of Elisha W. Finney, former executive vice president and chief financial officer at Varian Medical Systems (NYSE: VAR), to its Board of Directors and Audit Committee. Ms. Finney brings more than 25 years of financial and life science expertise to NanoString.

Her responsibilities at Varian included corporate accounting; corporate communications and investor relations; internal financial and compliance audit; risk management; tax and treasury and corporate information systems. She joined Varian in 1988 and was named vice president of finance and CFO in April, 1999. In January, 2005, she was promoted to senior vice president and given additional management responsibility for the corporate information systems group. Ms. Finney was named executive vice president of Varian in February, 2012. Ms. Finney currently serves on the board of directors at ICU Medical (NASDAQ: ICUI) and iRobot (NASDAQ: IRBT), and she previously served as a board member at Altera Corporation, Thoratec and Laserscope.

Ms. Finney earned her BA degree in risk management and insurance from the University of Georgia as well as an MBA degree from Golden Gate University in San Francisco.

“NanoString has a formidable combination of proprietary technology and visionary leadership that has established the company as an industry leader in translational medicine and molecular diagnostics,” said Ms. Finney. “I’m excited to have the opportunity to leverage my life science background and capital market expertise to help contribute to NanoString’s continued success.”

“Elisha brings decades of relevant life science experience and financial acumen that will help guide our strategic thinking as we grow the business and scale our operations,” said president and chief executive officer, Brad Gray. “Elisha is a well-respected leader in the life science industry, and we are delighted to have her join our Board of Directors.”

About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,500 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.
For more information, please visit .
NanoString, NanoString Technologies, the NanoString logo, nCounter and Prosigna are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.

Doug Farrell
Vice President, Investor Relations & Corporate Communications
Phone: 206-602-1768